linjc16/ctgov huggingface dataset:
Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia

Study Overview
=================
Brief Summary
-----------------
The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.

Official Title
-----------------
Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia. A Case-control Trial Nested in a Cohort

Conditions
-----------------
Cerebral Hypoxia, Ischemic Stroke

Intervention / Treatment
-----------------
* Other: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to the Rothschild Foundation within the first 24 hours of an acute neurological symptomatology related to : ischemic stroke eligible for a mechanical thrombectomy procedure subarachnoid haemorrhage due to aneurysmal rupture: patient with at least a modified Fisher scale 3 or 4 (Appendix 4) and a World Federation of Neurological Surgeons (WFNS) score of 2 or more intra-parenchymal haematoma with a Glasgow Coma Scale (GCS) strictly below 15. tissue-based transient ischaemic attack - no lesion found on imaging - with ABCD2≥ 2 (control group). Hospitalisation to the Fondation Adolphe de Rothschild Hospital at least 72 hours is planned Exclusion Criteria: Pre-existing functional and/or cognitive disability Patient under legal protection Pregnant or breastfeeding woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage | Other: Blood sampling<br>* Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion<br>|
| Control<br>Patients without cerebral hypoxia | Other: Blood sampling<br>* Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarker rates at day 0 | Biomarker: Neutro-Plaket aggregates, extra-cellular DNA networks, von Willebrand Factor | 24 hours |
Hyaluronic Acid Injection Post Arthroscopy - Does it Improve Immediate Function? Double Blind Controlled Prospective Study

Study Overview
=================
Brief Summary
-----------------
The proposed research is to examine the effect of injecting a large volume of HA (10cc) at the time of post arthroscopy suture removal (9-11 day post surgery), in patients with cartilage damage of ICRS grade 2 and above in one of the knee compartments.

Conditions
-----------------
Cartilage Injury

Intervention / Treatment
-----------------
* Device: Hyaluronic Acid Injection
* Drug: Saline Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Men and Women, who underwent arthroscopy of the knee with cartilage injury of ICRS grade 2 or higher in one of the compartments (in addition to other injuries such as meniscal tear and cruciate ligament). Exclusion Criteria: Patients with known rheumatic disorders. Known hypersensitivity to HA. Synovial diseases like PVNS, under 18y old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hyaluronic Acid Injection, pain, function<br> | Device: Hyaluronic Acid Injection<br> <br> |
| Placebo Comparator: Saline Injection<br> | Drug: Saline Injection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IKDC (the International Knee Documentation Committee) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adult Men and Women, who underwent arthroscopy of the knee with cartilage injury of ICRS grade 2 or higher
The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of CKD-497

Official Title
-----------------
A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-497

Conditions
-----------------
Respiratory Infection

Intervention / Treatment
-----------------
* Drug: CKD-497 200mg
* Drug: CKD-497 300mg
* Drug: CKD-497 placebo
* Drug: Comparator
* Drug: Comparator placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 19 ≤ age < 75 Subject with acute upper respiratory infection and acute bronchitis infection Subject who agreeds to participate in this clinical trial voluntarily Exclusion Criteria: Subject who need antibiotics treatment during the clinical trial Subject suffering from severe respiratory diseases such as pneumonia, asthma, chronic closed lung diseases (COPD), tuberculosis, bronchial enlargement, malignant tumors in the lungs, and chronic bronchitis during screening Subject who cannot participate in a clinical trial based on the PI's judgment

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CKD-497 200mg<br>CKD-497 200mg | Drug: CKD-497 200mg<br>* CKD-497 200mg<br>Drug: Comparator placebo<br>* Comparator placebo<br>|
| Experimental: CKD-497 300mg<br>CKD-497 300mg | Drug: CKD-497 300mg<br>* CKD-497 300mg<br>Drug: Comparator placebo<br>* Comparator placebo<br>|
| Active Comparator: Active Comparator<br>compartor | Drug: CKD-497 placebo<br>* Placebo of CKD-497<br>Drug: Comparator<br>* Comparator<br>|
| Placebo Comparator: Placebo<br>CKD-497 placebo and comparator placebo | Drug: CKD-497 placebo<br>* Placebo of CKD-497<br>Drug: Comparator placebo<br>* Comparator placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BSS(Bronchitis Severity Score) | 0(absent)   4(very severe), Total Score: 0 20 | 1 week | 
| SUM8(The 8-symptom related questions in the Daily Cough and Phlegm) | 0(Never)   4(always), Total Score: 0 32 | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute upper respiratory infection, Acute bronchitis
Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

Study Overview
=================
Brief Summary
-----------------
This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan. This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Official Title
-----------------
ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs

Conditions
-----------------
NIDDM

Intervention / Treatment
-----------------
* Drug: candesartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent Non-smokers Type II DM diagnosed patients Blood pressure < 135/90 Serum HbA1C > 7% Serum creatinine < 1mg% Urine microalbumin < 300 mg/day Body mass index (BMI) < 35 kg/m2 Exclusion Criteria: Insulin-dependent diabetic patients Patient with persistent microalbuminuria Patient with history of severe hypertension Congestive heart failure Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications. Patient with major hepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: candesartan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACE and ACE2 activities in monocytes |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
niddm, ace2, NIDDM patients
Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin

Study Overview
=================
Brief Summary
-----------------
To evaluate whether hepatitis B immune globulin with a high level of antibody against the hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis B virus, the single most important route of hepatitis spread in the entire Third World.

Detailed Description
-----------------
BACKGROUND: A baseline study on the vertical transmission of hepatitis B virus in Taiwan revealed that 15 percent of all pregnant women were persistent carriers of hepatitis B antigen and that 40 percent of their new babies developed a protracted antigenemia during the first 6 months of life. The incidence of acute hepatitis, cirrhosis, and hepatoma was high in Taiwan, and patients with these disorders had a fivefold to sixfold higher prevalence of hepatitis B antigen than healthy persons. Given the important public health problems of this disease in Taiwan and the rest of the Third World, this trial sought to answer the important question of whether hepatitis B immune globulin with a high level of antibody against the antigen would be of utility in combating the problem. Two hundred and five babies were accepted into the study, which was actually conducted on Taiwan through a contract to the Community Blood Council of Greater New York. Only those babies born of mothers who had HBsAg complement fixation titers of 1:8 or greater were included in these studies. At birth, blood was obtained from the mothers and cord blood from the infants. Follow-up bloods were obtained from both the mother and baby when the infants were 1, 3, 6, 12, 24 and 36 months of age. In addition, all household family contacts were bled at least once during this period. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. A total of 205 neonates were assigned to treatment with high-titer hepatitis B immune globulin, standard immune globulin, or albumin placebo within 72 hours of delivery. The study completion date listed in this record was obtained from the Query/View/Report (QVR) System.

Conditions
-----------------
Hepatitis B, Hepatitis, Viral, Human, Liver Diseases

Intervention / Treatment
-----------------
* Drug: immunoglobulins, intravenous


Participation Criteria
=================
Eligibility Criteria
-----------------
Boy and girl infants, birth to 3 years, born to mothers who were hepatitis B surface antigen carriers.

Ages Eligible for Study
-----------------
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: immunoglobulins, intravenous|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Gradual Vs. Rapid Buprenorphine Detoxification - 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.

Official Title
-----------------
Gradual Vs. Rapid Buprenorphine Detoxification

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 33 Years
Maximum Age: 43 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Retention |  |  | 
| Observed withdrawal rating |  |  | 
| Opioid agonist rating |  |  | 
| Opioid antagonist rating |  |  |
Cancersensor Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Observational, non randomized study aimed at measuring the effect of chemotherapy in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer.

Official Title
-----------------
Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : Effect of Chemotherapy on Cancerous Proliferation Based on the Dynamic Excretion of Urinary Nucleosides.

Conditions
-----------------
Metastatic Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically-confirmed metastatic colorectal cancer; 0 to 3 prior chemotherapy lines; Signed informed consent; Good understanding of the protocol and of the follow-up; Estimated life expectancy exceeding 3 months; At least one measurable metastatic lesion (RECIST criteria); Performance Status (WHO) of 0 to 2; Good haematological, hepatic and renal functions. Exclusion Criteria: More than 2 surgical resections of metastases from colorectal cancer; Poor performance status (>2); Poor haematological, hepatic or renal functions; Uncontrolled chronic disease; Serious unhealed wound, ulcer or fracture within the previous month; Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion; Pregnancy or breast-feeding during the previous month; Transmeridian trip of more than 4 time zones within the prior 2 weeks; Person with legal restriction to participate into clinical research, according to the current law in France.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Patients with metastatic colorectal cancer treated with chemotherapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of chemotherapy on urinary excretion of modified nucleosides | 1 urine sample per day 3 days before and 14 days after beginning of chemotherapy Measurement of modified nucleosides, cortisol and 6-sulfatoxymelatonin concentration 1 saliva sample : Measurement of Clock genes polymorphisms expression | 17 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal, Cancer, Metastatic, Chronotherapy, Urine, Nucleosides, Chemotherapy, Treated with chemotherapy
China Red Eye Study on Allergic Conjunctivitis

Study Overview
=================
Brief Summary
-----------------
This study is the first multi-center cross-sectional study on the diagnosis and misdiagnosis of allergic conjunctivitis in the ophthalmology clinic in China. It provides a clinical basis for the standardized diagnosis and treatment of allergic eye diseases.

Detailed Description
-----------------
Allergic conjunctivitis is a common disease in ophthalmology. The European Allergy Association, Japan, the United States and other countries have clear diagnostic criteria or guidelines for the definition and diagnosis of allergic diseases and allergic conjunctivitis. However, China is currently lacking related guidelines. Allergic conjunctivitis has some of the same symptoms and signs as other infections/non-infectious conjunctival inflammation. When the symptoms and signs are atypical, it is prone to missed diagnosis and misdiagnosis, resulting in prolonged disease duration, drug abuse and waste of medical resources. The current abuse of antibiotics is considered to be a huge problem in the treatment of ocular surface diseases. A study in our country believes that the rate of misdiagnosis of dry eye is as high as 66.2%, and most of them are misdiagnosed as chronic conjunctivitis, resulting in frequent using a variety of antibiotic eye drops. At present, the misdiagnosis of allergic conjunctivitis and the abuse of antibiotics caused by misdiagnosis in China are still unclear, therefore clinical research is urgently needed. We intend to use this study to understand the status of diagnosis and treatment of allergic conjunctivitis in China, and provide clinical evidence for the standard diagnosis and treatment of allergic eye diseases.

Official Title
-----------------
Current Status of Diagnosis and Treatment of Allergic Conjunctivitis in Chinese Ophthalmology Clinic

Conditions
-----------------
Allergic Conjunctivitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients whose clinical diagnosis is allergic conjunctivitis. Exclusion Criteria: The investigator believes that there are any unsuitable reasons for participating in the trial.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specific diagnosis of the patients | the investigators record the patients' specific diagnosis (such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis，and etc) on questionnaire when the patient come | Until the study completion, up to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
misdiagnose, mistreatment, antibiotics
Short Term Outcomes of Children With Acute Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
The study is a chart review of all children admitted over a two year period with the diagnosis of acute respiratory distress syndrome. Short term outcomes, such as mortality, length of ventilation and length of stay, will be reviewed. Factors that impact these outcomes will also be reviewed.

Detailed Description
-----------------
We would like to conduct a chart review of all patients with pediatric ARDS hospitalized in the PICU at Columbus Children's Hospital in the last two years. Patients would be included for review if they met the clinical criteria for ARDS. These criteria are: rapidly progressive respiratory failure, severe hypoxemia (PaO2/FiO2 < 200), and evidence of bilateral pulmonary infiltrate on chest radiography. We estimate 40-50 patients will meet criteria. Once criteria are met, patient charts will be pulled or reviewed electronically. We will then compose a database that includes no patient identifiers but contains information regarding the cause, length, and outcome of the ARDS admission and PICU stay. Factors such as nutritional status, antibiotic and muscle relaxant use, and type of ventilation used will be examined. Other care-related variables will be included if they are felt to impact outcome during the review process. The database will then be analyzed and information regarding pediatric ARDS outcomes in our institution will be published. We anticipate that examining the factors that impact short term outcomes in pediatric ARDS will lead to research possibilities regarding ways to improve both short and long term outcomes in children with this illness. We propose that reviewing the disease entity as a whole will lead to improvements in caring for children with the disease, and eventually bring about a decline in mortality rates.

Conditions
-----------------
Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rapidly progressive respiratory failure, Severe hypoxemia (PaO2/FiO2 < 200), Evidence of bilateral pulmonary infiltrate on chest radiography 0-18 years of age Exclusion Criteria: Heart failure Cardiac shunt present

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |